Crawford Strunk1, Immacolata Tartaglione2, Connie M Piccone3, Raffaella Colombatti4, Biree Andemariam5, Deepa Manwani6, Ashya Smith7, Haikel Haile7, Esther Kim7, Samuel Wilson7, Eugenia Vicky Asare8, Angela Rivers9, Fatimah Farooq7, Rebekah Urbonya7, Donna Boruchov10, Gifty Dankwah Boatemaa11, Silverio Perrotta2, Ivy Ekem8, Laura Sainati4, Sudha Rao10, William Zempsky12, Fredericka Sey8, Charles Antwi-Boasiako13, Catherine Segbefia14, Baba Inusa15, Andrew D Campbell16. 1. Department of Pediatric Hematology/Oncology, ProMedica Russell J. Ebeid Children's Hospital, Toledo, OH, USA. Electronic address: Crawford.Strunk@ProMedica.org. 2. Department of Women, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy. 3. Pediatric Hematology, Carle Foundation Hospital, Urbana, IL, USA. 4. Clinic of Pediatric Hematology Oncology, Department of Women's and Child Health, Azienda Ospedaliera-Università di Padova, Padova, Italy. 5. New England Sickle Cell Institute, Division of Hematology-Oncology, Neag Comprehensive Cancer Center, UCONN Health, University of Connecticut, Farmington, CT, USA. 6. Department of Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY, USA. 7. Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA. 8. Ghana Institute of Clinical Genetics, Korle Bu Teaching Hospital, Accra, Ghana. 9. UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA. 10. Department of Child Health, Korle Bu Teaching Hospital, Accra, Ghana. 11. Department of Physiology, University of Ghana Medical School, University of Ghana, Accra, Ghana. 12. Division of Pain and Palliative Care, Department of Pediatrics, University of Connecticut School of Medicine, Connecticut Children's Medical Center, Hartford, CT, USA. 13. Department of Physiology, University of Ghana Medical School, University of Ghana, Accra, Ghana; Ghana Institute of Clinical Genetics, Korle Bu Teaching Hospital, Accra, Ghana. 14. Department of Child Health, Korle Bu Teaching Hospital, Accra, Ghana; Department of Child Health, University of Ghana Medical School, University of Ghana, Accra, Ghana. 15. Department of Pediatric Haematology, Evelina Children's Hospital, Guy's and St. Thomas NHS Trust, London, UK. 16. Division of Pediatric Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA; Department of Pediatrics, Divison of Hematology, Children's National Hospital, George Washington University School of Medicine Health Sciences, Washington, DC, USA.
Abstract
BACKGROUND: Sickle cell disease (SCD) is characterized by frequent, unpredictable pain episodes and other vaso-occlusive crises (VOCs) leading to significant healthcare utilization. VOC frequency is often an endpoint in clinical trials investigating novel therapies for this devastating disease. PROCEDURE: The Consortium for the Advancement of Sickle Cell Research (CASiRe) is an international collaboration investigating clinical severity in SCD using a validated questionnaire and medical chart review standardized across four countries (United States, United Kingdom, Italy and Ghana). RESULTS: This study, focused on pain crisis incidence and healthcare utilization, included 868 patients, equally represented according to age and gender. HgbSS was the most common genotype. Patients from Ghana used the Emergency Room/Day Hospital for pain more frequently (annualized mean 2.01) than patients from other regions (annualized mean 1.56 U.S.; 1.09 U.K.; 0.02 Italy), while U.K. patients were hospitalized for pain more often (annualized mean: U.K. 2.98) than patients in other regions (annualized mean 1.98 U.S.; 1.18 Ghana; Italy 0.54). Italy's hospitalization rate for pain (annualized mean: 0.57) was nearly 20 times greater than its emergency room/day hospital only visits for pain (annualized mean: 0.03). When categorized by genotype and age, similar results were seen. CONCLUSIONS: Geographic differences in pain crisis frequency and healthcare utilization may correlate with variable organization of healthcare systems among countries and should be considered regarding trial design, endpoints, and analysis of results when investigating novel agents for clinical benefit.
BACKGROUND: Sickle cell disease (SCD) is characterized by frequent, unpredictable pain episodes and other vaso-occlusive crises (VOCs) leading to significant healthcare utilization. VOC frequency is often an endpoint in clinical trials investigating novel therapies for this devastating disease. PROCEDURE: The Consortium for the Advancement of Sickle Cell Research (CASiRe) is an international collaboration investigating clinical severity in SCD using a validated questionnaire and medical chart review standardized across four countries (United States, United Kingdom, Italy and Ghana). RESULTS: This study, focused on pain crisis incidence and healthcare utilization, included 868 patients, equally represented according to age and gender. HgbSS was the most common genotype. Patients from Ghana used the Emergency Room/Day Hospital for pain more frequently (annualized mean 2.01) than patients from other regions (annualized mean 1.56 U.S.; 1.09 U.K.; 0.02 Italy), while U.K. patients were hospitalized for pain more often (annualized mean: U.K. 2.98) than patients in other regions (annualized mean 1.98 U.S.; 1.18 Ghana; Italy 0.54). Italy's hospitalization rate for pain (annualized mean: 0.57) was nearly 20 times greater than its emergency room/day hospital only visits for pain (annualized mean: 0.03). When categorized by genotype and age, similar results were seen. CONCLUSIONS: Geographic differences in pain crisis frequency and healthcare utilization may correlate with variable organization of healthcare systems among countries and should be considered regarding trial design, endpoints, and analysis of results when investigating novel agents for clinical benefit.
Authors: Donna K McClish; Wally R Smith; Bassam A Dahman; James L Levenson; John D Roberts; Lynne T Penberthy; Imoigele P Aisiku; Susan D Roseff; Viktor E Bovbjerg Journal: Pain Date: 2009-07-23 Impact factor: 6.961
Authors: Alison P Galvani; Alyssa S Parpia; Eric M Foster; Burton H Singer; Meagan C Fitzpatrick Journal: Lancet Date: 2020-02-15 Impact factor: 79.321
Authors: O S Platt; D J Brambilla; W F Rosse; P F Milner; O Castro; M H Steinberg; P P Klug Journal: N Engl J Med Date: 1994-06-09 Impact factor: 91.245
Authors: S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds Journal: N Engl J Med Date: 1995-05-18 Impact factor: 91.245
Authors: Matthew M Heeney; Carolyn C Hoppe; Miguel R Abboud; Baba Inusa; Julie Kanter; Bernhards Ogutu; Patricia B Brown; Lori E Heath; Joseph A Jakubowski; Chunmei Zhou; Dmitry Zamoryakhin; Tsiri Agbenyega; Raffaella Colombatti; Hoda M Hassab; Videlis N Nduba; Janet N Oyieko; Nancy Robitaille; Catherine I Segbefia; David C Rees Journal: N Engl J Med Date: 2015-12-08 Impact factor: 91.245
Authors: Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah Journal: JAMA Date: 2014-09-10 Impact factor: 56.272